Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Dimercaptosuccinic acid (DMSA) is scientifically validated for the treatment of lead poisoning. DMSA is a water-soluble chelating agent that binds to heavy metals, such as lead, in the body and facilitates their excretion through urine. Its use is supported by numerous clinical studies and is recognized by major health organizations, including the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

Randomized controlled trials and clinical experience have demonstrated that DMSA effectively lowers blood lead levels in children and adults with moderate to severe lead poisoning. It is considered less toxic and better tolerated compared to older chelators like dimercaprol (British Anti-Lewisite, BAL) and ethylenediaminetetraacetic acid (EDTA). DMSA’s oral administration is an advantage, especially in pediatric populations. Guidelines recommend DMSA for children with blood lead levels above specific thresholds (typically >45 μg/dL) and in some adults with symptomatic or significant exposure.

Its safety profile is well established, with mild side effects such as gastrointestinal upset and occasional neutropenia. DMSA does not appear to significantly deplete essential minerals when used for short courses, but monitoring is recommended. Overall, DMSA’s use in lead poisoning is evidence-based, with high-quality support from both clinical trials and expert consensus guidelines.

More about Dimercaptosuccinic acid (DMSA)
More about Lead Poisoning

Other ingredients used for Lead Poisoning

Other health conditions supported by Dimercaptosuccinic acid (DMSA)

Products containing Dimercaptosuccinic acid (DMSA)